Navigation Links
Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
Date:5/27/2008

KENILWORTH, N.J., May 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that Janet M. Barth has been appointed vice president, investor relations, effective immediately.

In this role, Barth will be responsible for developing, implementing and continually improving a comprehensive global investor relations program for Schering-Plough. She will lead the formulation and execution of external and internal investor communications plans to support Schering-Plough's business objectives. She also will partner with the company's senior management team on matters pertaining to the investment community and individual shareholders.

Barth reports to Alex Kelly, group vice president, global communications and investor relations. She assumes the investor relations responsibilities that were previously fulfilled by Kelly, who was named to his current expanded role in October 2007.

Barth most recently served as senior vice president, investor relations and corporate communications, for Adams Respiratory Therapeutics, which was a newly public specialty pharmaceutical company. In that role, she established, developed and directed comprehensive investor relations and corporate communications programs for the company prior to its acquisition by Reckitt Benckiser in January 2008.

Previously, Barth was employed for 14 years by Schering-Plough, where she held various positions of increasing responsibility, including that of director, investor relations. Barth holds a Bachelor of Arts degree in policy and management studies from Dickinson College, Carlisle, Pa., and a Master of Business Administration degree from Seton Hall University, South Orange, N.J. She joined the National Investor Relations Institute (NIRI) in 1996 and currently is a member of NIRI's New York and Virtual Chapters. Barth completed a 12-month leadership development program with Women Unlimited LEAD (Leadership Education and Development) in 2005.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... FREDERICK, Md. , Feb. 8, 2016 /PRNewswire/ ... advanced consumer medical devices, announced today that it ... for administrative proceedings from the Securities and Exchange ... Richard Staelin , Chairman of the Board ... Donnell Professor of Business Administration at The Fuqua ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... a wide range of loose, bulk foods at various stages of the production ... also used to inspect large bulk products post packaging such as sacks of ...
(Date:2/8/2016)... Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral ... will present information about the company,s programs at the BIOCEO conference ... York City . --> --> ... EST. Registered attendees can request a one on one meeting through ... --> New York City . ...
(Date:2/8/2016)... Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, Feb. ... Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create a ...
Breaking Biology Technology:
(Date:2/1/2016)... YORK , Feb. 1, 2016  Today, the ... Association (AHA) announced plans to develop a first of ... computing power of IBM Watson. In the first application ... AHA, IBM (NYSE: IBM ), and Welltok will ... and health assessments with cognitive analytics, delivered on Welltok,s ...
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
(Date:1/21/2016)... , January 21, 2016 ... a new market research report "Emotion Detection and Recognition ... Software Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020", published by MarketsandMarkets, the ... to reach USD 22.65 Billion by 2020, at ...
Breaking Biology News(10 mins):